PDF Cover

Endovascular Robot System Market

The market for Endovascular Robot System was estimated at $1.4 billion in 2025; it is anticipated to increase to $3.0 billion by 2030, with projections indicating growth to around $6.1 billion by 2035.

Report ID:DS1801595
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Medical Device
Endovascular Robot System
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Endovascular Robot System Market Outlook

Revenue, 2025

$1.4B

Forecast, 2035

$6.1B

CAGR, 2026 - 2035

15.4%

The Endovascular Robot System industry revenue is expected to be around $1.7 billion in 2026 and expected to showcase growth with 15.4% CAGR between 2026 and 2035. This strong growth trajectory highlights the increasing strategic importance of endovascular robot systems in modern interventional procedures. The rising prevalence of cardiovascular and neurovascular diseases is significantly driving adoption, as healthcare providers seek more precise and minimally invasive treatment solutions. Hospitals are increasingly investing in robotic-assisted platforms to enhance procedural accuracy, reduce radiation exposure for clinicians, and improve patient outcomes. Additionally, growing demand for advanced imaging integration and real-time navigation is reinforcing the relevance of robotic systems in complex vascular interventions. Expanding healthcare infrastructure in emerging markets and increasing focus on value-based care are further accelerating adoption, positioning these systems as a critical component in next-generation interventional suites.

Endovascular robot systems are advanced medical platforms designed to assist physicians in performing minimally invasive vascular procedures with enhanced precision and control. These systems typically include robotic manipulators, operator consoles, imaging integration, and software-driven navigation tools that enable remote catheter and guidewire manipulation. Key applications span interventional cardiology, peripheral vascular procedures, and neurovascular interventions, where accuracy and stability are essential. Recent trends driving demand include the integration of AI-assisted navigation, improved haptic feedback mechanisms, and compatibility with a wide range of interventional devices. Additionally, increasing emphasis on reducing operator fatigue and radiation exposure is encouraging adoption across hospitals and specialty clinics, supporting the broader shift toward technologically advanced and patient-centric care delivery.

Endovascular Robot System market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2025-2035
Endovascular Robot System Market Outlook

Market Key Insights

  • The Endovascular Robot System market is projected to grow from $1.4 billion in 2025 to $6.1 billion in 2035. This represents a CAGR of 15.4%, reflecting rising demand across Percutaneous Coronary Intervention and Peripheral Vascular Interventions.

  • The market exhibits an oligopolistic structure with only 7 prominent players, with Siemens Healthcare and Microbot Medical Inc. commanding the largest shares.

  • U.S. and China are the top markets within the Endovascular Robot System market and are expected to observe the growth CAGR of 13.9% to 18.5% between 2025 and 2030.

  • Emerging markets including India, Brazil and Turkey are expected to observe highest growth with CAGR ranging between 10.8% to 16.2%.

  • Slow adoption of 5G Enabled Teleoperated Vascular Care transition within key players in Endovascular Robot System market is creating a revenue window for adjacent and alternate markets like Magnetic catheter navigation systems and to improve its use-case penetration in Pci and Pvi applications and expected to capture $183 million revenue from existing Endovascular Robot System market.

  • The Endovascular Robot System market is set to add $4.6 billion between 2025 and 2035, with manufacturer targeting PVI & Neurosurgery Application projected to gain a larger market share.

  • With

    rising incidence of complex vascular disease and shortage of specialist interventionalists accelerate endovascular robot system adoption, and

    AI enabled navigation enhances precision and efficiency for endovascular robot systems, Endovascular Robot System market to expand 319% between 2025 and 2035.

endovascular robot system market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Endovascular Robot System - Country Share Analysis

Opportunities in the Endovascular Robot System

GCC private hospital groups are also building hybrid OR and cath lab facilities to draw medical tourists and high end cardiovascular patients. Robotic PCI provides sub millimeter precision and reduced radiation and marketing differentiation for complex CTO and multivessel cases. The market for coronary endovascular robot systems will expand the most because of turnkey EPC partnerships and managed service agreements and payer collaboration for bundled payments and cross border Centers of Excellence networks that connect flagship hubs.

Growth Opportunities in North America and Asia-Pacific

The North American endovascular robot system market advances because of high procedure numbers in neurovascular and structural heart programs and FDA clearance of portfolios and favorable reimbursement for complex PCI and peripheral interventions. The market opportunities exist in comprehensive stroke centers and IDNs that want to reduce radiation exposure and achieve precise navigation and remote robotic capabilities to handle staffing shortages. The market leadership belongs to Siemens Healthineers and niche innovators who use hospital GPO contracts and imaging integration partnerships to determine market share. The market will expand because of capital expenditure cycles and AI navigation systems and outcome data that demonstrates robotics shortens fluoroscopy time and enhances operational efficiency.
The Asia Pacific endovascular robot system market experiences rapid growth because of increasing cardiovascular and cerebrovascular diseases and expanding catheterization labs and government support for digital health initiatives. The market presents three main opportunities which include China and India localization and distributor access to tier 2 hospitals and cost optimized platforms that match tender procurement and value based care models. The market competition consists of multinational companies alongside agile domestic OEMs which differentiate themselves through NMPA/PMDA approvals and KOL led trials and imaging robot integration. The path to success depends on joint venture manufacturing operations and local stent and guidewire compatibility and scalable training programs and teleproctoring services that will drive neurointervention adoption despite payment and capital expenditure limitations.

Market Dynamics and Supply Chain

01

Driver: Rising incidence of complex vascular disease and shortage of specialist interventionalists accelerate endovascular robot system adoption

The increasing prevalence of atherosclerotic and neurovascular disease also stems from global aging and diabetes and hypertension which results in more complex lesions that require minimally invasive treatment. Hospitals need robotic platforms to achieve precision navigation and catheter stability and reduce radiation exposure because of challenging anatomies and extended fluoroscopy times and distant target locations. The limited number of neurointerventionalists and endovascular specialists who work outside urban areas restricts patients from receiving timely medical care. Teleproctoring systems together with potential telerobotics and standardized workflows help extend expert reach and maintain consistency in medical care. The neurovascular application market will also experience its fastest growth through robotic assisted mechanical thrombectomy and aneurysm embolization procedures. Stroke networks and hub and spoke models increase the need for scalable and reproducible intervention capabilities.
The combination of AI enabled vessel segmentation with path planning and motion compensation technologies enables semi autonomous operations and precise torque management and automated wire transfer capabilities. The integration of OCT/IVUS and 3D angiography roadmaps with robots enables both reduced fluoroscopy time and contrast use and enhanced crossing success in difficult lesion procedures. The decision support and automation modules enhance procedural efficiency and reproducibility which strengthens the clinical and economic case for adoption. The most significant immediate benefit will also occur in complex coronary PCICTO crossings and bifurcation stenting procedures that operate in high volume cath labs which aim to achieve consistent results.
02

Restraint: High total cost of ownership and uncertain reimbursement

The adoption of endovascular robot systems faces barriers because of high initial costs and service agreements and proprietary single use disposables that reduce hospital profitability and make value analysis approvals more difficult especially in interventional cardiology and neurovascular service lines. The uncertain nature of reimbursement payments combined with unclear payment increments for robotic endovascular procedures creates challenges for ROI calculations which leads to longer procurement times and focuses demand on well funded tertiary centers while community hospitals and ASCs choose conventional catheter based interventions. The price sensitivity drives customers toward leasing and pay per use models which decreases average selling prices and reduces installed base growth and consumable pull through while slowing down market velocity and vendor revenue scalability.
03

Opportunity: Peripheral arterial disease interventions in U.S. community hospitals driving Endovascular Robot System adoption and Neurovascular stroke thrombectomy programs in India and Southeast Asia advancing Endovascular Robot System uptake

Community and rural hospitals experience three major challenges which include insufficient interventional staff, radiation safety restrictions and increasing peripheral vascular disease cases. Robotic assisted angioplasty with intravascular navigation enables hospitals to expand their case mix without requiring permanent specialist staff while providing nighttime coverage and enhancing operator comfort. The peripheral vascular robot system market will experience its fastest expansion through femoropopliteal and below the knee lesion procedures because of GPO contracts and leasing models and telerobotic proctoring partnerships with academic vascular centers.
The worlds highest stroke burden exists in India and Southeast Asia but there are not only enough thrombectomy capable centers available. Public tertiary networks require scalable neurointervention capacity together with standardized quality and radiation dose reduction. The combination of endovascular robotics with microcatheter automation and AI guided roadmap alignment allows for accelerated training and remote mentorship. The neurovascular robot platform will experience the fastest regional growth because of government tenders and local distributor alliances and outcomes linked procurement criteria.
04

Challenge: Clinical integration barriers and evidence gap

The steep learning curve, proctoring requirements, and workflow disruption in the angiography suite slow clinician adoption, while device compatibility constraints and IT integration needs hinder seamless catheter navigation across diverse cases. The lack of extensive clinical and health economic data showing better results and reduced radiation exposure and shorter procedure times compared to manual methods prevents payers from supporting robotic systems and clinicians from feeling confident in their use which leads hospitals to choose next generation fluoroscopy, IVUS/OCT, or image guided software upgrades instead. The uneven utilization rates and limited procedure indications restrict system use to specific cases which results in reduced consumables demand and creates fragmented market dynamics that slow down the diffusion curve across interventional cardiology, peripheral vascular, and neurointerventional settings.

Supply Chain Landscape

1

Raw Material Supply

TE Connectivity Ltd.Amphenol CorporationAnalog Devices Inc.
2

Component Manufacturing

Siemens Healthcare Private LimitedStereotaxis Inc.Microbot Medical Inc.
3

System Integration

Robocath S.A.SRemedy Robotics Inc.Sentante
4

End Use Applications

Interventional cardiologyNeurovascular interventionPeripheral vascular intervention
Endovascular Robot System - Supply Chain

Use Cases of Endovascular Robot System in Percutaneous Coronary Intervention & Peripheral Vascular Interventions

Percutaneous Coronary Intervention : The robotic assisted PCI procedure employs bedside cassette based drive systems which operate guidewires and balloon/stent catheters through systems like Siemens Healthineers Corindus CorPath GRX and Robocath R One. The shielded cockpit allows operators to perform telemanipulation of devices which enables them to cross lesions and deliver stents and optimize angioplasty procedures. The system provides sub millimeter precision while minimizing radiation and contrast exposure and enhancing procedural ergonomics through consistent results. The largest installed base and strong clinical evidence belong to Siemens while Robocath expands its presence in Europe and Asia through its compact and cost efficient platform.
Peripheral Vascular Interventions : The same catheter/guidewire drive medical robotic systems used for iliac, renal, and femoropopliteal lesions perform peripheral vascular interventions to enable precise ballooning, atherectomy support, and stent graft placement. The teleoperated control system provides better stability in complex anatomy and reduces both operator radiation exposure and orthopedic strain while enhancing device accuracy. Siemens Healthineers maintains top regulatory approvals and reference facilities for peripheral indications while Hansen Medical Magellan demonstrated multi directional steerability in its legacy system and Robocath continues to develop PVI clinical programs through hospital partnership growth.

Impact of Industry Transitions on the Endovascular Robot System Market

As a core segment of the Medical Device industry, the Endovascular Robot System market develops in line with broader industry shifts. Over recent years, transitions such as 5G Enabled Teleoperated Vascular Care and Data Centric, Interoperable Cath Labs have redefined priorities across the Medical Device sector, influencing how the Endovascular Robot System market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

5G Enabled Teleoperated Vascular Care

Endovascular robot systems now perform teleoperated surgery by integrating robotic catheter navigation with AI guided imaging and low latency 5G connectivity to enable remote interventions that deliver higher precision and lower radiation exposure and reproducible outcomes. The technological advancement enables stroke thrombectomy and peripheral artery disease care to reach underserved areas while maximizing procedural efficiency and staffing capabilities in hybrid ORs. A regional stroke network demonstrates the FDA clearance of robotic thrombectomy technology at its hub hospital to reduce door to reperfusion times and transfer expenses while establishing new reimbursement methods for telehealth based interventional cardiology and radiology. The model drives cybersecurity enhancements and payer coverage trials and medical liability standards which attract telecom companies and cloud providers and malpractice insurance organizations.
02

Data Centric, Interoperable Cath Labs

The evolution of robots creates standardized workflows through EHR integration and imaging interoperability and force feedback haptics and analytics that reduce contrast usage and increase throughput. A health system integrates a vendor agnostic robot with fluoroscopy and intravascular imaging under outcome based contracts while using digital twin training to reduce learning curves for structural heart interventions and obtain CE Mark indications which streamlines OEM partnerships and supply chains.